Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7199MR)

This product GTTS-WQ7199MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7199MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11218MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ9195MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ15902MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ6061MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ6646MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ6158MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ6416MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ8577MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5F9-G4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW